Sparrow Pharmaceuticals, Inc. has announced positive phase 2 clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, in adults with...
SOTIO Biotech has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of...
Biogen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular...
Servier has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. for up to $2.65bn, including an upfront payment...
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (Kisunla, from Eli Lilly and Company),...
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, has announced that the U.S. Food and Drug Administration (FDA)...
JJP Biologics has announced positive interim data from its ongoing phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89...
This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.
Base to Base biotech...